Pomerantz alerts investors on Bright Minds, Ethos, Aurora and Everest
Pomerantz LLP announced investor investigations into Bright Minds Bioscience, Ethos Technologies and Aurora Innovation, and reminded investors that a class action has been filed against Everest Group. The Bright Minds investigation follows an FDA partial clinical hold on a proposed BMB-101 trial over toxicity and data concerns; Ethos’s follows a media report alleging reliance on multilevel-marketing agencies and agents with licensing issues; and Aurora’s follows a delayed driverless-truck rollout and a 40% cut to its 2026 revenue guidance. In each case, the companies’ shares fell after the relevant news. The Everest lawsuit concerns allegations of securities misconduct tied to rising U.S. casualty losses, reserve increases and related disclosures; investors seeking lead-plaintiff appointment must act by December 28, 2026.




